Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.61 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.61 |
| ▸ | CCR1 | P32246 | 1/20 | 0.61 |
| ▸ | CCR2 | P41597 | 1/20 | 0.61 |
| ▸ | CCR5 | P51681 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373050 | 0.89 | CCR3 (1.00) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5387442 | 0.88 | CCR3 (0.84) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5387780 | 0.86 | CCR3 (0.79) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5383616 | 0.86 | CCR3 (0.91) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5380562 | 0.84 | CCR3 (1.00) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5383608 | 0.81 | CCR3 (0.70) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5378309 | 0.81 | CCR3 (0.70) | CCR3CYP2D6CXCR1CXCR2CCR1 | |
| SCHEMBL5382039 | 0.80 | CCR3 (1.00) | CCR3 | |
| SCHEMBL5382031 | 0.80 | CCR3 (1.00) | CCR3 | |
| SCHEMBL5393300 | 0.79 | CCR3 (0.80) | CCR3CYP2D6CXCR1CXCR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | CCR3 18/4885CYP2D6 3192/4885CXCR1 11/4885 |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CYP2D6 3121/4885CXCR1 21/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CYP2D6 3241/4885CXCR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.